Brought to you by 
GSK partners with Pentraxin on amyloidosis treatment
26 Mar 2009
Executive Summary
GlaxoSmithKline and private UK biotech Pentraxin Therapeutics (spun off from University College London) have agreed to collaborate on the latter's preclinical small molecule/antibody combination for amyloidosis, a protein misfolding disorder in which amyloid accumulates in organs and tissues such as the heart, kidneys, liver, spleen, nervous system, and GI tract.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK partners with Pentraxin on amyloidosis treatment
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice